An Information Service of the Division of Medical Assistance

North Carolina
Special Medicaid Pharmacy
Newsletter

Number 276 November 2017

In This Issue...

**Opioid Dependence Therapy Agents Coverage Changes**
Opioid Dependence Therapy Agents Coverage Changes

Effective Nov. 1, 2017, Suboxone Film (the preferred product in this class) will no longer require a prior approval for coverage. The beneficiary must be receiving the medication for a diagnosis of Opioid Dependence and the prescriber must have a special DEA number that begins with “X”. The maximum covered daily dose is 24 mg/day.

For coverage of Bunavail Film (non-preferred), the beneficiary must be receiving the medication for a diagnosis of opioid dependence and the prescriber must have a special DEA number that begins with “X”. The beneficiary must have tried and failed on Suboxone Film or have a documented medical reason why they cannot use Suboxone Film. The maximum covered daily dose is 12.6mg/day.

For coverage of buprenorphine-naloxone sublingual tablets (non-preferred), the beneficiary must be receiving the medication for a diagnosis of opioid dependence and the prescriber must have a special DEA number that begins with “X”. The beneficiary must have tried and failed on Suboxone Film or have a documented medical reason why they cannot use Suboxone Film. The maximum covered daily dose is 24mg/day.

For coverage of Zubsolv (non-preferred), the beneficiary must be receiving the medication for a diagnosis of opioid dependence and the prescriber must have a special DEA number that begins with “X”. The beneficiary must have tried and failed on Suboxone Film or have a documented medical reason why they cannot use Suboxone Film. The maximum covered daily dose is 17.1mg/day.

A prior approval is required for coverage of buprenorphine sublingual tablets (single ingredient), which are also non-preferred. The prescriber must have a special DEA number that begins with “X” and the beneficiary must be unable to take Suboxone Film. Acceptable reasons include: beneficiaries who are pregnant or nursing, (documentation should be provided with the prior approval request) and beneficiaries with an allergy to naloxone (documentation should be provided with the prior approval request), which includes the following signs and symptoms: rashes, hives, pruritus, bronchospasm, angioneurotic edema and/or anaphylactic shock. Initial requests and renewal requests require documentation as to why the beneficiary cannot use a combination product.

Requests for buprenorphine (single ingredient) may be approved for up to nine months during pregnancy and in two month increments thereafter during breast feeding. The maximum daily dose covered is 24 mg/day. Initial requests and renewals require documentation as to why the beneficiary cannot use a combination (buprenorphine-naloxone) product. Requests for buprenorphine (single ingredient) product may be approved for up to 12 months for beneficiaries with a documented allergy to naloxone. The maximum daily dose covered is 24 mg/day. Initial requests and renewal requests require documentation as to why the beneficiary cannot use a combination (buprenorphine-naloxone) product.
John C. Stancil, Jr., R.Ph.
Director, Pharmacy and DMEPOS Programs
Division of Medical Assistance
N.C. Department of Health and Human Services

Rick Paderick, R.Ph.
Pharmacy Director
NCTracks
CSRA

Sandra Terrell, MS, RN
Director of Clinical
Division of Medical Assistance
N.C. Department of Health and Human Services

Lori Landman
Deputy Executive Account Director
NCTracks
CSRA

Dave Richard
Deputy Secretary for Medical Assistance
Division of Medical Assistance
N.C. Department of Health and Human Services

Paul Guthery
Executive Account Director
NCTracks
CSRA

Nancy Henley, MD
Chief Medical Officer
Division of Medical Assistance
N.C. Department of Health and Human Services

Desiree Elekwa-Izuakor, Pharm D, MBA, CPC-A
Outpatient Pharmacy Program Manager
Division of Medical Assistance
N.C. Department of Health and Human Services